Surely this company must come up against Mesoblast’s extensive patents and IP .
Direct Biologics ExoFlo do not have a truly novel therapy.
And Mesoblast are years ahead , decades of work in.
Success by competitors & increasing competition and moves towards FDA approvals and support - only increases the likelihood of an acquirer seeking to take over Mesoblast instead , and speed into first place in the field.
https://www.mesoblast.com/company/overview
https://directbiologics.com/exoflo/
Cell Therapy News/Articles, page-15691
-
- There are more pages in this discussion • 2,130 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
-0.055(4.66%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.18 | $1.18 | $1.13 | $4.824M | 4.236M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 25589 | $1.13 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 10000 | 1 |
View Market Depth
| Last trade - 16.10pm 17/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |